Cargando…
Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
Oral antiplatelet drugs are crucially important for patients with acute coronary syndrome or stable coronary artery disease undergoing percutaneous coronary intervention (PCI). In recent decades, several clinical trials have focused on reducing periprocedural ischemic events in patients undergoing P...
Autores principales: | Capodanno, Davide, Milluzzo, Rocco P., Angiolillo, Dominick J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6906352/ https://www.ncbi.nlm.nih.gov/pubmed/31823688 http://dx.doi.org/10.1177/1753944719893274 |
Ejemplares similares
-
Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
por: De Luca, Leonardo, et al.
Publicado: (2021) -
The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary
por: Iversen, Allan, et al.
Publicado: (2008) -
Influence of glycoprotein IIb/IIIa inhibitors on bleeding events after successful resuscitation and percutaneous coronary intervention
por: Biever, Paul Marc, et al.
Publicado: (2019) -
Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease
por: Suwaidi, Jassim Al, et al.
Publicado: (2001) -
Acute Cerebral Infarction Following Intravenous Glycoprotein IIb/IIIa Inhibitor for Acute Myocardial Infarction
por: Choi, Woong Gil, et al.
Publicado: (2011)